Adial Pharmaceuticals Shares Are Trading Higher After the Company Announced It Received FDA Feedback for Its Vitro Bridging Strategy of AD04 and Will Proceed to Manufacture Clinical Supplies for Its Upcoming Phase 3 Clinical Trial.

BenzingaFeb 25 09:05 ET

Express News | Adial Pharmaceuticals Receives Positive Response From FDA Meeting Regarding Proposed in Vitro Bridging Strategy for Ad04

ReutersFeb 25 09:00 ET

Adial Pharmaceuticals Receives Positive Response From FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

GlobeNewswireFeb 25 09:00 ET

EXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder

BenzingaFeb 25 08:30 ET

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

GlobeNewswireFeb 12 09:00 ET

Express News | EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'New Patent Expands Patent Estate Covering Adial's Unique Molecular Genetic Approach to Diagnosing and Potentially Treating Alcohol and Drug Dependence'

BenzingaFeb 12 08:30 ET